Clinical Trials Directory

Trials / Unknown

UnknownNCT02799992

Pseudo-PDT in Central Serous Chorioretinopathy

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
22 (estimated)
Sponsor
Università degli Studi di Brescia · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Acute central serous chorioretinopathy (CSC) is a common disorder in middle-aged patients, characterized by serous retinal detachment in the macular region. We evaluated half-dose verteporfin photodynamic therapy (hd-PDT) versus 689 nm laser treatment in chronic CSC. Twenty-two eyes of 22 patients with symptomatic chronic CSC were randomized in a 1:1 ratio to receive hd-PDT (group 1) or 689-LT delivering 95 J/cm2 by application of an intensity of 805 mW/cm2 over 118 seconds. Best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography findings were compared between groups.

Conditions

Interventions

TypeNameDescription
PROCEDURE689 nm Laser Treatment of the Macula
PROCEDUREHalf Dose Photodynamic Therapy

Timeline

Start date
2016-06-01
Primary completion
2016-09-01
Completion
2016-09-01
First posted
2016-06-15
Last updated
2016-06-15

Source: ClinicalTrials.gov record NCT02799992. Inclusion in this directory is not an endorsement.

Pseudo-PDT in Central Serous Chorioretinopathy (NCT02799992) · Clinical Trials Directory